Atossa Therapeutics(US:ATOS) Prnewswireยท2025-08-28 12:30Core Viewpoint - Atossa Therapeutics is actively engaging with investors and the biotech community to discuss its clinical advancements and future milestones, particularly focusing on its lead product candidate, (Z)-endoxifen, which aims to innovate breast cancer treatment and prevention [1][3]. Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment and prevention through innovative science and patient-focused solutions [6]. - The company's lead product candidate, (Z)-endoxifen, is being developed as a therapy across the breast cancer spectrum, including both prevention and treatment settings [6]. Group 2: Upcoming Events - Dr. Steven Quay, Chairman and CEO of Atossa, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET [1][3]. - The live presentation will be webcast, with a replay available for approximately 90 days on the company's investor website [4]. Group 3: Clinical Progress - Dr. Quay will provide updates on the clinical progress of (Z)-endoxifen, highlighting its dual mechanisms of action as a Selective Estrogen Receptor Modulator (SERM) that may offer a differentiated solution for breast cancer prevention and treatment [3]. - Recent feedback from regulatory advisors has been encouraging, which could potentially accelerate the company's development path [3].